MDT

86.12

+0.38%↑

121.33

+2.77%↑

VEEV

167.59

+1.04%↑

HQY

85.7

+1.56%↑

NEOG

9.53

+3.03%↑

MDT

86.12

+0.38%↑

121.33

+2.77%↑

VEEV

167.59

+1.04%↑

HQY

85.7

+1.56%↑

NEOG

9.53

+3.03%↑

MDT

86.12

+0.38%↑

121.33

+2.77%↑

VEEV

167.59

+1.04%↑

HQY

85.7

+1.56%↑

NEOG

9.53

+3.03%↑

MDT

86.12

+0.38%↑

121.33

+2.77%↑

VEEV

167.59

+1.04%↑

HQY

85.7

+1.56%↑

NEOG

9.53

+3.03%↑

MDT

86.12

+0.38%↑

121.33

+2.77%↑

VEEV

167.59

+1.04%↑

HQY

85.7

+1.56%↑

NEOG

9.53

+3.03%↑

Inicio・Lista de Acciones・Pliant Therapeutics Inc

Pliant Therapeutics Inc

Abierto

1.32 0.76

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

1.29

Máximo

1.33

Métricas clave
By Trading Economics
Ingresos	2.7M -24M
BPA	-0.354
Empleados	49
EBITDA	-5.3M -28M

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 Meses	+103.82% upside

Dividendos
By Dow Jones
Próximas Ganancias	7 may 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	-624K 80M
Apertura anterior	0.56
Cierre anterior	1.32

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

1.43 / 1.6 Soporte y Resistencia

Pliant Therapeutics Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

16 abr 2026, 23:26 UTC

Acciones populares

Stocks to Watch: Netflix, Alcoa, Knight-Swift, NiSource

16 abr 2026, 20:41 UTC

Principales Movimientos del Mercado

Netflix Shares Slide After 2Q Outlook Misses Wall Street's Expectations

16 abr 2026, 23:49 UTC

Charlas de Mercado

Amplitude's Pivot to Oil-Linked Supply Deal Catches Bull's Eye -- Market Talk

16 abr 2026, 23:45 UTC

Charlas de Mercado

Nikkei May Decline After Hitting Record High -- Market Talk

16 abr 2026, 23:33 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Gold Edges Higher on Hopes for U.S.-Iran Deal -- Market Talk

16 abr 2026, 22:51 UTC

Charlas de Mercado

Netflix Sees Signs That Podcasts May Boost Engagement -- Market Talk

16 abr 2026, 22:08 UTC

Ganancias

Netflix Chair Reed Hastings to Leave Board in June -- 3rd Update

16 abr 2026, 22:06 UTC

Ganancias

Lundin Mining: Earnings From Discontinued Ops in 1Q Expected to Be Positively Impacted by Unaudited Gain on Disposal of Eagle Mine, Totaling Approximately $4M >LUN.T

16 abr 2026, 22:06 UTC

Ganancias

Lundin Mining: Pre-Announces Items Impacting 1Q Results

16 abr 2026, 22:06 UTC

Ganancias

Lundin Mining: Items of Significant Impact in 1Q Expected to Include Unaudited Realized Losses on Derivative Contracts of Approximately $13M, Primarily Related to Gold Collar Contracts >LUN.T

16 abr 2026, 22:06 UTC

Ganancias

Lundin Mining: Rev in 1Q Expected to Be Positively Impacted by Unaudited Provisional Pricing Adjustments on Prior-Period Concentrate Sales of Approximately $22M on Pre-Tax Basis >LUN.T

16 abr 2026, 22:06 UTC

Ganancias

Lundin Mining: Adjustments Primarily Include Upward Adjustments in Relation to Prior-Period Metal Sales >LUN.T

16 abr 2026, 20:50 UTC

Charlas de Mercado

Ganancias

Tech, Media & Telecom Roundup: Market Talk

16 abr 2026, 20:50 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

16 abr 2026, 20:50 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Basic Materials Roundup: Market Talk

16 abr 2026, 20:50 UTC

Charlas de Mercado

Ganancias

Health Care Roundup: Market Talk

16 abr 2026, 20:49 UTC

Ganancias

SpaceX Is Ready to Go Public. The Stock Market Is Its Rocket. -- Barrons.com

16 abr 2026, 20:43 UTC

Ganancias

Update: Netflix Stock Falls on Weak Guidance. Founder Reed Hastings Is Leaving the Board. -- Barrons.com

16 abr 2026, 20:40 UTC

Charlas de Mercado

Ganancias

Global Equities Roundup: Market Talk

16 abr 2026, 20:40 UTC

Charlas de Mercado

Ganancias

Netflix Says Engagement Quality Hits New High -- Market Talk

16 abr 2026, 20:30 UTC

Acciones populares

Stocks to Watch: TSMC, Abbott Laboratories, Nvidia, Netflix -- WSJ

16 abr 2026, 20:25 UTC

Ganancias

Netflix Stock Falls on Weak Guidance. Founder Reed Hastings Is Leaving the Board. -- Barrons.com

16 abr 2026, 20:23 UTC

Ganancias

These Stocks Are Today's Movers: AMD, Intel, TSMC, Abbott, Hims, Corning, Schwab, Polaris, and More -- Barrons.com

16 abr 2026, 20:19 UTC

Ganancias

Netflix Guidance Disappoints. The Stock Is Down. -- Barrons.com

16 abr 2026, 20:17 UTC

Ganancias

Alcoa: Alumina Costs in the Aluminum Segment Are Expected to Be Favorable by Approximately $20M Sequentially >AA

16 abr 2026, 20:17 UTC

Ganancias

Alcoa: Based on Higher LME and Midwest Premium Pricing and Expected Higher Shipments, Section 232 Tariff Costs on U.S. Imports of Aluminum From Canada Expected to Increase $35M Sequentially >AA

16 abr 2026, 20:16 UTC

Ganancias

Alcoa: Expects 2026 Total Aluminum Segment Production and Shipments Ranging Between 2.4M and 2.6M Metric Tons, and Between 2.6M and 2.8M Metric Tons, Respectively >AA

16 abr 2026, 20:16 UTC

Ganancias

Alcoa: Expects 2026 Total Aluminum Segment Production and Shipments to Remain Unchanged From Its Prior Projection >AA

16 abr 2026, 20:16 UTC

Ganancias

Alcoa: Expects 2026 Total Alumina Segment Production and Shipments Ranging Between 9.7M to 9.9M Metric Tons, and Between 11.8M and 12.0M Metric Tons, Respectively >AA

16 abr 2026, 20:16 UTC

Ganancias

Alcoa: Expects 2026 Total Alumina Segment Production and Shipments to Remain Unchanged From Prior Projection >AA

Comparación entre iguales

Cambio de precio

Pliant Therapeutics Inc previsión

Precio Objetivo

By TipRanks

103.82% repunte

Estimación a 12 Meses

Media 2.67 USD 103.82%

Máximo 3 USD

Mínimo 2 USD

De acuerdo con 5 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Pliant Therapeutics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

5 ratings

Comprar

Mantener

Vender

De acuerdo con 5 analistas que ofrecen calificaciones bursátiles a para Pliant Therapeutics Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

1.43 / 1.6Soporte y Resistencia

Recent bearish events outweigh bullish events.

There is one bearish event.

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.